Medication Options for Early Awakening Insomnia

Recommended Medications

The American Academy of Sleep Medicine recommends suvorexant or low-dose doxepin for sleep maintenance insomnia, with suvorexant carrying a WEAK strength according to GRADE methodology 1, 2
Low-dose doxepin is specifically recommended for sleep maintenance insomnia, with doses of 3-6 mg demonstrating efficacy for maintaining sleep and increasing deep sleep duration 1
The American Academy of Sleep Medicine recommends eszopiclone (2-3 mg at bedtime; 1 mg in elderly) for both sleep onset and maintenance insomnia with intermediate duration of action and no short-term usage restriction 3, 4, 1
Temazepam (15-30 mg at bedtime; 7.5 mg in elderly) is recommended for both sleep onset and maintenance insomnia with short-to-intermediate acting properties 4, 1

The American Academy of Sleep Medicine does not recommend zaleplon, triazolam, and ramelteon for early awakening insomnia due to their short duration of action 4, 1
Trazodone is NOT recommended by the American Academy of Sleep Medicine for insomnia treatment due to limited evidence and significant side effects 1

The American Academy of Sleep Medicine suggests starting with suvorexant or low-dose doxepin as first-line pharmacologic options for early awakening 1
If these are ineffective or not tolerated, consider eszopiclone or temazepam for their intermediate duration of action 4, 1
All benzodiazepine receptor agonists carry FDA warnings regarding complex sleep behaviors, daytime memory impairment, and potential association with dementia in observational studies 5
Dose adjustments are mandatory in elderly, debilitated patients, or those with hepatic impairment—typically reducing doses by 50% 4
Avoid combining these medications with alcohol, other CNS depressants, or during sleep restriction 4, 6
Administration on empty stomach is advised to maximize effectiveness 6
Abrupt discontinuation of benzodiazepines can produce withdrawal symptoms including rebound insomnia 6

The American Academy of Sleep Medicine rates all pharmacologic recommendations as "WEAK" according to GRADE methodology, indicating that while benefits outweigh harms, many patients might reasonably choose not to use these treatments 1
Cognitive behavioral therapy for insomnia (CBT-I) should be considered first-line treatment before or alongside pharmacotherapy due to sustained benefits without tolerance or adverse effects 1

The American Academy of Sleep Medicine clinical practice guideline found that 30 mg of temazepam represents the upper limit studied in clinical trials, with significant efficacy demonstrated by 40-45 minute reductions in sleep latency compared to placebo in adult patients with insomnia 7, 8, 9, 10, 11
Total sleep time increased by 53-54.6 minutes at the 30 mg dose, and the number of awakenings decreased by 1.0-1.24 compared to placebo in adult patients with insomnia 9, 11
The American Academy of Sleep Medicine recommends escalating to 30 mg only if the 15 mg dose proves insufficient after an adequate trial in adult patients with insomnia 10